## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-herniated-disc`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-herniated-disc/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-herniated-disc/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-herniated-disc/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-herniated-disc/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-herniated-disc/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-herniated-disc/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-herniated-disc` v2 · content_hash `1dd1191705f8a23a…` · thread_head genesis · 34 DIVs
- **thesis (c1):** SS-31 reduced apoptosis and pyroptosis in lipopolysaccharide-exposed nucleus pulposus cells via mitochondrial ROS scavenging (preclinical).
  - c3 [human/active] SS-31 received FDA approval for Barth syndrome in 2025 with prior Phase II/III data in mitochondrial conditions (human).
  - c5 [human/active] ARA-290 reduced neuropathic pain and supported nerve function in human diabetic neuropathy studies (human).
  - c2 [preclinical/active] SS-31 improved locomotor recovery in a mouse spinal cord contusion model via mitochondrial bioenergetics preservation (preclinical).
  - c4 [preclinical/active] BPC-157 improved functional recovery after rat spinal cord compression injury (preclinical).
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-herniated-disc/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-herniated-disc/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-herniated-disc`
- **title:** SS-31 for Herniated Disc: Mitochondrial Targeting in Disc Repair Pathways
- **url:** https://miscsubjects.com/a/ss-31-herniated-disc
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:04.892Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have Herniated disc

A herniation happens when disc material pushes through the outer ring. It often starts from degenerative disc changes where the weakened annulus tears under load. The herniation itself is an acute event on top of chronic degeneration. Nerve compression or chemical irritation causes pain while the disc structure remains compromised.

Breakdown occurs across layers. In the disc matrix, collagen and proteoglycans degrade and disc height drops. Inflammation involves chronic signaling without resolution that stalls repair. Nerves get irritated or compressed as the disc bulges. Blood supply is limited because discs are avascular so repair depends on diffusion and slower supply means slower repair.

If breakdown outruns repair in any of these layers, the condition persists. Peptides in scope are studied for repair pathways rather than symptom suppression.

## Why SS-31 (Elamipretide) might help you

1. You have herniated disc — breakdown is outpacing repair.
2. Therefore for you: If the mitochondrial layer is part of your problem, SS-31 (Elamipretide) is discussed because it targets repair at the cellular energy level — not because it masks pain.
3. This article centers SS-31 (Elamipretide); see other sections for BPC-157, TB-500, ARA-290 — different layers, same condition.

Disc cells rely on mitochondria for energy to maintain matrix and resist oxidative stress. If mitochondrial dysfunction accelerates cell death in nucleus pulposus cells, SS-31 concentrates in the inner mitochondrial membrane and scavenges reactive oxygen species while supporting membrane stability. In one in vitro study using nucleus pulposus cells exposed to lipopolysaccharide, SS-31 reduced apoptosis, pyroptosis, and inflammation markers through mitochondrial ROS reduction and preserved mitochondrial dynamics (preclinical tier). A mouse spinal cord injury model showed SS-31 improved locomotor recovery, reduced lesion size, and supported neuronal preservation via mitochondrial bioenergetics (preclinical). Cartilage injury models demonstrated protection against chondrocyte apoptosis and matrix loss even when dosing started hours after impact (preclinical). Human data for SS-31 comes from trials in mitochondrial disorders such as Barth syndrome where functional improvements were observed (human tier); it received FDA approval for that rare condition in 2025. No human trials exist for herniated disc.

## Why BPC-157 might help you

1. You have herniated disc — breakdown is outpacing repair.
2. What keeps failing: Poor blood supply at injury, weak collagen organization, slow tissue turnover.
3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.
4. Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.

If avascular disc regions limit nutrient delivery after herniation, angiogenesis pathways could matter for matrix turnover. Rat spinal cord compression studies showed BPC-157 improved functional recovery and tissue healing after injury (preclinical). No direct human trials for disc herniation exist; one small human study examined intra-articular knee injections for pain (human tier, limited scope). Most evidence remains animal or in vitro.

## Why TB-500 might help you

1. You have herniated disc — breakdown is outpacing repair.
2. Layer breaking down: Inflammation — Chronic inflammatory signaling without resolution stalls repair.
3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

If unresolved inflammation blocks cell migration into damaged disc areas, actin-sequestering effects of thymosin beta-4 fragments may promote migration and remodeling. In vitro work on intervertebral disc cells suggests support for regeneration pathways (preclinical). Human data for TB-500 in musculoskeletal tissues including disc is absent; evidence is weighted toward wound healing and ocular contexts (preclinical dominant).

## Why ARA-290 might help you

1. You have herniated disc — breakdown is outpacing repair.
2. Layer breaking down: Nerves — Nerve roots get irritated or compressed as disc bulges.
3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

If nerve root irritation drives pain and limits function, selective agonism at the innate repair receptor may shift inflammation toward resolution and support small fiber recovery. Clinical studies in diabetic neuropathy showed reduced pain and improved nerve function markers (human tier). Preclinical neuropathy models demonstrated reprogramming of inflammatory milieu into repair signals (preclinical). Direct disc herniation data is absent.

## How these fit together

Three degeneration layers — disc/tissue, inflammation/repair cells, nerves — map to three repair pathways in the recovery stack.
- SS-31 (Elamipretide) → mitochondrial
- BPC-157 → structure / tissue
- TB-500 → inflammation clearance / repair-cell migration
- ARA-290 → nerve / innervation

Primary focus of this slug: SS-31 (Elamipretide). Others are in scope because the same condition breaks down on multiple layers. Mitochondrial support from SS-31 may preserve disc cell viability while BPC-157 addresses vascular delivery, TB-500 aids cell recruitment, and ARA-290 targets nerve irritation. The stack addresses separate failure points without overlap in primary mechanisms.

## What the evidence actually shows

Human trials: SS-31 has Phase II/III data in mitochondrial myopathy and heart failure plus recent approval for Barth syndrome (human). ARA-290 has published neuropathy trials (human). BPC-157 and TB-500 have essentially no interventional human trials for disc conditions.

Preclinical: SS-31 shows direct effects on disc nucleus pulposus cells and spinal injury models (multiple rat/mouse/in vitro). BPC-157 and TB-500 show tissue repair signals in spinal cord or disc cell studies (rat/in vitro). ARA-290 shows nerve repair in neuropathy models (preclinical + human).

Anecdotal: Reddit threads discuss BPC-157/TB-500 combinations for back pain and herniated discs with mixed self-reports of pain reduction; one user noted success with spinal injury alongside PRP. Limited X discussion appears in semantic searches.

## What scientists say

Researchers note SS-31 protects mitochondria in stressed disc cells and may slow degenerative cascades when applied early. Neuropathy work on ARA-290 highlights reprogramming of inflammation toward repair. Overall literature calls for more human disc-specific studies; current data does not prove reversal of herniation.

## What people say on Reddit

Users in r/bpc_157 and r/backpain report trying BPC-157 plus TB-500 for bulging or herniated discs, citing reduced sciatica or improved mobility in some cases while others note limited structural change. Anecdotes emphasize combination use and caution against expecting full regeneration.

## What people say on X

Posts are sparse; occasional mentions link peptides to back recovery but lack detailed disc-specific outcomes or verified before-after data.

## What we do not know

No randomized human trials test any of these peptides for herniated disc healing or symptom relief. Long-term effects on disc height or re-herniation rates are unknown. Optimal timing relative to acute injury versus chronic degeneration remains unstudied in humans.

## Safety and limits

SS-31 holds FDA approval only for Barth syndrome. The other peptides lack regulatory approval for any indication in most jurisdictions. Evidence for disc applications is preliminary and largely preclinical. Individual responses vary; consult qualified medical professionals for personal health decisions. This article presents studied pathways only.

## Claims (5)

- **c5** [human w=0.8] ARA-290 reduced neuropathic pain and supported nerve function in human diabetic neuropathy studies (human).
  - who_claims: grok/grok-4.3
  - sources: s5
- **c3** [human w=0.8] SS-31 received FDA approval for Barth syndrome in 2025 with prior Phase II/III data in mitochondrial conditions (human).
  - who_claims: grok/grok-4.3
  - sources: s3
- **c1** [preclinical w=0.5] SS-31 reduced apoptosis and pyroptosis in lipopolysaccharide-exposed nucleus pulposus cells via mitochondrial ROS scavenging (preclinical).
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [preclinical w=0.5] SS-31 improved locomotor recovery in a mouse spinal cord contusion model via mitochondrial bioenergetics preservation (preclinical).
  - who_claims: grok/grok-4.3
  - sources: s2
- **c4** [preclinical w=0.5] BPC-157 improved functional recovery after rat spinal cord compression injury (preclinical).
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-herniated-disc/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `1fa74a870b312ded`

### s1 · pubmed · http_403
- title: The mitochondrial antioxidant SS-31 attenuated lipopolysaccharide-induced apoptosis and pyroptosis of nucleus pulposus cells
- url: https://www.tandfonline.com/doi/abs/10.1080/10715762.2021.2018426
- summary: In vitro study on disc nucleus pulposus cells showing SS-31 mitochondrial protective effects.
- quote: This study found that SS-31 ameliorated lipopolysaccharide (LPS)-induced loss of cell viability, ROS production, and apoptosis in NP cells... via scavenging ROS and maintaining the stability of mitochondrial dynamics
- claim_ids: c1
- hash: `5db536b4bc294f70`

### s2 · pubmed · ok
- title: Elamipretide (SS-31) Promotes Recovery by Preserving Mitochondrial Bioenergetics and Neural Remodeling after Spinal Cord Injury
- url: https://pubmed.ncbi.nlm.nih.gov/42082001/
- summary: Mouse SCI model demonstrating SS-31 benefits via mitochondria.
- quote: In a mouse thoracic contusion model, SS-31 treatment significantly enhanced locomotor recovery and gait performance... reduced lesion pathology and increased neuronal preservation
- claim_ids: c2
- hash: `2489d78c7f211fe1`

### s3 · news · ok
- title: FDA Approval for Mitochondrial Therapeutic Elamipretide, Formerly SS-31
- url: https://www.fightaging.org/archives/2025/10/fda-approval-for-mitochondrial-therapeutic-elamipretide-formerly-ss-31/
- summary: Reports 2025 FDA approval for Barth syndrome.
- quote: The recent FDA approval of elamipretide is for the treatment of a rare disease
- claim_ids: c3
- hash: `abbdfe2a1d1cf369`

### s4 · pubmed · ok
- title: Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats
- url: https://pubmed.ncbi.nlm.nih.gov/31266512/
- summary: Rat spinal cord injury study with BPC-157.
- quote: BPC 157 therapy was administered... Assessments were performed at 1, 4, 7, 15, 30, 90, 180, and 360 days after injury
- claim_ids: c4
- hash: `9b29da5b8c0dfae0`

### s5 · pubmed · ok
- title: Targeting the innate repair receptor to treat neuropathy
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/
- summary: Review of ARA-290 in neuropathy including clinical data.
- quote: These experimental and clinical studies show that ARA290 effectively reprograms a proinflammatory, tissue-damaging milieu into one of healing and tissue repair
- claim_ids: c5
- hash: `1fa74a870b312ded`

## Provenance (2 model passes)
- chain valid: yes · head: `9ce9b4d23533dabc`

- write · grok/grok-4.3 · 2026-06-29T23:53 · hash `2ee956403b69`
- voxel_divide · owner · 2026-07-17T02:42 · hash `9ce9b4d23533`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-herniated-disc/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-herniated-disc/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-herniated-disc","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-herniated-disc|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-herniated-disc|tier|assertion`
- **iMessage ask:** `ss-31-herniated-disc|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-herniated-disc`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-herniated-disc/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-herniated-disc/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*